Tag: MAF

SUMMARY: Researchers are studying if hemangiosarcoma (HSA) subtypes influence how affected dogs respond to treatment – a step toward precision medicine for these patients.

THE PROBLEM: Hemangiosarcoma is a serious and usually fatal cancer of dogs. Most dogs die of the disease by within 4-6 months post-diagnosis, even with aggressive treatment. However, some  research suggests that hemangiosarcoma is not one disease but comprised of different subtypes, and  these subtypes might be related to longevity and response to therapy.

THE PROJECT: This research team has previously found that dogs with one type of HSA are more likely to live longer than dogs that have a different type of HSA. This may explain why current treatments  fail to help most dogs with HSA live longer despite aggressive care. To take a closer look at this  finding, researchers will identify the HSA type or signature in tumors from dogs that have lived longer  than other dog patients with HSA. The team is using data from a study in progress to inform their  evaluation of archived tissues to assess prevalence and survival.

PROJECT UPDATE: The team encountered an obstacle when the library generation for the RNA-sequencing portion of the project did not work – the team is in the process of redoing the RNA-extraction and sequencing.
Continue reading “Research Update MAF D24CA-535-April 2026: Studying Hemangiosarcoma Subtypes and Treatment Response” →

SUMMARY: Researchers will look for mutations in hemangiosarcoma cases as a step toward developing new therapies.

THE PROBLEM: Hemangiosarcoma (HSA) is a highly malignant disease and is common in breeds including Golden Retrievers, German Shepherd, Boxer, and others. When detected, HSA is often advanced and spreads to other locations. Effective treatment of HSA is currently lacking, and affected dogs have a grave outcome. Thus, research that leads to effective intervention of this terrible disease is urgently needed. Continue reading “Research Update MAF D24CA-536: Search for Immune Stimulating Mutations in Canine Hemangiosarcoma” →

SUMMARY: Researchers are studying if hemangiosarcoma (HSA) subtypes influence how affected dogs respond to treatment – a step toward precision medicine for these patients.

THE PROBLEM: Hemangiosarcoma is a serious and usually fatal cancer of dogs. Most dogs die of the disease by  within 4-6 months post-diagnosis, even with aggressive treatment. However, some research suggests that hemangiosarcoma is not one disease but comprised of different subtypes, and these subtypes might be related to  longevity and response to therapy.

THE PROJECT: This research team has previously found that dogs with one type of HSA are more likely to live longer than dogs that have a different type of HSA. This may explain why current treatments fail to help most dogs with HSA live longer despite aggressive care. To take a closer look at this finding, researchers will identify the HSA type or signature in tumors from dogs that have lived longer than other dog patients with HSA. The team is using data from a study in progress to inform their evaluation of archived tissues to assess prevalence and survival. Continue reading “Research Update MAF D24CA-535: Studying Hemangiosarcoma Subtypes and Treatment Response” →